Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
9.76
-0.30 (-2.94%)
Mar 31, 2025, 12:39 PM EDT - Market open

Rapport Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Cash & Equivalents
56.8170.1731.16
Short-Term Investments
248.4877.31-
Cash & Short-Term Investments
305.28147.4831.16
Cash Growth
107.00%373.31%-
Prepaid Expenses
0.31.50.11
Restricted Cash
0.110.09-
Other Current Assets
4.121.81-
Total Current Assets
309.8150.8731.27
Property, Plant & Equipment
4.9740.34
Long-Term Deferred Charges
-0.3-
Other Long-Term Assets
0.160.25-
Total Assets
314.93155.4231.6
Accounts Payable
1.952.51.45
Accrued Expenses
6.085.630.21
Current Portion of Leases
0.740.67-
Total Current Liabilities
8.778.81.66
Long-Term Debt
-4.210.44
Long-Term Leases
0.741.48-
Total Liabilities
9.5114.4812.1
Common Stock
0.0400.03
Additional Paid-In Capital
429.6619.80.56
Retained Earnings
-123.75-45.44-10.65
Comprehensive Income & Other
-0.520-
Total Common Equity
305.43-25.63-10.06
Shareholders' Equity
305.43140.9419.51
Total Liabilities & Equity
314.93155.4231.6
Total Debt
1.486.3510.44
Net Cash (Debt)
303.8141.1320.72
Net Cash Growth
115.26%581.01%-
Net Cash Per Share
14.6593.7326.66
Filing Date Shares Outstanding
36.54.170.78
Total Common Shares Outstanding
36.584.170.78
Working Capital
301.04142.0729.61
Book Value Per Share
8.35-6.15-12.95
Tangible Book Value
305.43-25.63-10.06
Tangible Book Value Per Share
8.35-6.15-12.95
Machinery
3.781.760.3
Construction In Progress
0.430.030.06
Leasehold Improvements
0.280.26-
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q